Long-Term Proactive Management of Psoriasis Vulgaris with Fixed-Dose Combination of Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam: Results from a Phase III Randomized Controlled Trial

Psoriasis Vulgaris ◽

Controlled Trial ◽

Phase Iii ◽

Fixed Dose ◽

Randomized Controlled ◽

Proactive Management ◽

Abstract not available.

18223 Long-term proactive management of psoriasis vulgaris with fixed-dose combination of 0.005% calcipotriene and 0.064% betamethasone dipropionate foam: Results of a phase III randomized controlled trial

10.1016/j.jaad.2020.06.919 ◽

2020 ◽

Vol 83 (6) ◽

pp. AB208

Author(s):

Mark Lebwohl ◽

Jean-Philippe Lacour ◽

Monika Liljedahl ◽

Charles Lynde ◽

Marie Holst Mørch ◽

...

Keyword(s):

Psoriasis Vulgaris ◽

Controlled Trial ◽

Phase Iii ◽

Fixed Dose ◽

Randomized Controlled ◽

Proactive Management ◽

12797 Safety of long-term proactive management with fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam in patients with psoriasis vulgaris: Results of a phase III, multicenter, randomized, 52-week, vehicle-controlled trial

10.1016/j.jaad.2020.06.091 ◽

2020 ◽

Vol 83 (6) ◽

pp. AB1

Author(s):

Mark Lebwohl ◽

Jean Philippe Lacour ◽

Monika Liljedahl ◽

Charles Lynde ◽

Marie Mørch ◽

...

Keyword(s):

Psoriasis Vulgaris ◽

Controlled Trial ◽

Fixed Dose Combination ◽

Phase Iii ◽

Fixed Dose ◽

Proactive Management ◽

Safety of Long-Term Proactive Management with Fixed-Dose Combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam in Patients with Psoriasis Vulgaris: Results of a Phase III, Multicentre, Randomized, 52-Week, Vehicle-Controlled Trial

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.4.supp.31 ◽

2020 ◽

Vol 4 (5) ◽

pp. s31

Author(s):

Mark Lebwohl ◽

Jean-Philippe Lacour ◽

Monika Liljedahl ◽

Charles Lynde ◽

Marie H Mørch ◽

...

Keyword(s):

Psoriasis Vulgaris ◽

Controlled Trial ◽

Fixed Dose Combination ◽

Phase Iii ◽

Fixed Dose ◽

Proactive Management ◽

Abstract not available.

16830 Results from the open-label treatment period of a long-term proactive management phase III trial using fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam

10.1016/j.jaad.2020.06.835 ◽

2020 ◽

Vol 83 (6) ◽

pp. AB187

Author(s):

Mark Lebwohl ◽

Jean Philippe LACOUR ◽

Monika Liljedahl ◽

Charles Lynde ◽

Marie Mørch ◽

...

Keyword(s):

Treatment Period ◽

Fixed Dose Combination ◽

Phase Iii ◽

Fixed Dose ◽

Open Label ◽

Phase Iii Trial ◽

Proactive Management ◽

Efficacy of a Fixed-Dose Combination of Ibuprofen and Acetaminophen Compared With Individual Monocomponents in Adult Male Subjects With Endotoxin-Induced Fever: A Randomized Controlled Trial

Clinical Therapeutics ◽

10.1016/j.clinthera.2021.05.004 ◽

2021 ◽

Author(s):

William Smith ◽

Rina Leyva ◽

David Kellstein ◽

Edmund Arthur ◽

Mario Cruz-Rivera

Keyword(s):

Adult Male ◽

Controlled Trial ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Randomized Controlled ◽

Dose Combination ◽

Male Subjects

The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (DaivobetR/ DovobetR) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial

British Journal of Dermatology ◽

10.1111/j.1365-2133.2004.06134.x ◽

2004 ◽

Vol 151 (3) ◽

pp. 663-668 ◽

Cited By ~ 36

Author(s):

P.C.M. Van De Kerkhof

Keyword(s):

Quality Of Life ◽

Psoriasis Vulgaris ◽

Controlled Trial ◽

Randomized Controlled ◽

The Impact

Efficacy and safety of calcipotriene plus betamethasone dipropionate gel compared to tacalcitol ointment and gel vehicle alone in patients with psoriasis vulgaris: A randomized controlled trial

10.1016/j.jaad.2009.11.513 ◽

2010 ◽

Vol 62 (3) ◽

pp. AB134

Keyword(s):

Psoriasis Vulgaris ◽

Controlled Trial ◽

Efficacy And Safety ◽

Randomized Controlled

Efficacy of long-term (104-week) treatment with apremilast in patients with psoriatic arthritis: Results from a phase III, randomized, controlled trial and open-label extension

10.1016/j.jaad.2016.02.968 ◽

2016 ◽

Vol 74 (5) ◽

pp. AB248

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Phase Iii ◽

Open Label ◽

Randomized Controlled ◽

Open Label Extension

1236 EFFECTS OF LONG-TERM ANDROGEN REPLACEMENT THERAPY ON PHYSICAL AND MENTAL STATUS IN AGING MALES WITH LATE-ONSET HYPOGONADISM: RESULTS OF A PHASE III, MULTICENTER, RANDOMIZED, CONTROLLED TRIAL

The Journal of Urology ◽

10.1016/j.juro.2013.02.2590 ◽

2013 ◽

Vol 189 (4S) ◽

Author(s):

Hiroyuki Konaka ◽

Kazuhiro Sugimoto ◽

Kazuyoshi Sigehara ◽

Yoshifumi Kadono ◽

Eitetsu Koh ◽

...

Keyword(s):

Replacement Therapy ◽

Mental Status ◽

Late Onset ◽

Controlled Trial ◽

Phase Iii ◽

Randomized Controlled ◽

Multicenter Randomized Controlled Trial ◽

Late Onset Hypogonadism

Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: Results from a phase III, randomized, controlled trial (ESTEEM 1)

10.1016/j.jaad.2014.01.722 ◽

2014 ◽

Vol 70 (5) ◽

pp. AB174 ◽

Cited By ~ 1

Keyword(s):

Controlled Trial ◽

Severe Psoriasis ◽

Phase Iii ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Phosphodiesterase 4 Inhibitor